Related Experiment Video
Updated: Mar 14, 2026
11:29
Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
Published on: August 15, 2025
2.8K
Pharmacological modulation in mesial temporal lobe epilepsy: Current status and future perspectives
Antonio Gambardella1, Angelo Labate1, Pierangelo Cifelli2
1Institute of Neurology, University Magna Græcia, Catanzaro, Italy; Institute of Molecular Bioimaging and Physiology of the National Research Council, Catanzaro, Italy.
Pharmacological Research
|September 24, 2016
Summary
Mesial temporal lobe epilepsy (MTLE) with hippocampal sclerosis involves complex genetic and environmental factors. Targeting neuroinflammation and GABAergic transmission may offer new therapeutic strategies for drug-resistant epilepsy.
Area of Science:
- Neuroscience
- Epileptology
- Immunology
Background:
- Mesial temporal lobe epilepsy (MTLE) often co-occurs with hippocampal sclerosis (Hs).
- MTLE-Hs is a dynamic condition influenced by genetic and environmental factors.
- Underlying brain injury may precede epilepsy onset by years.
Purpose of the Study:
- To review current research on disease-modifying strategies for pharmacoresistant MTLE.
- To explore the interplay between neuroinflammation and GABAergic transmission in MTLE.
- To highlight potential therapeutic targets for MTLE-Hs.
Main Methods:
- Review of clinical observations in human MTLE patients.
- Analysis of experimental findings from preclinical studies.
- Focus on molecular and cellular alterations in epileptogenic networks.
Main Results:
- Neuroinflammation and GABAergic system dysfunction are key features of MTLE.
- Modulation of epileptogenic networks shows therapeutic potential.
- Crosstalk between immune response and inhibitory neurotransmission is evident.
Conclusions:
- Pharmacological targeting of neuroinflammation and GABAAR modulation offers promising avenues for treating drug-resistant MTLE.
- Understanding the complex molecular pathways is crucial for developing novel disease-modifying therapies.
- Combined therapeutic strategies may be necessary for effective MTLE management.
More Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
01:14Antiepileptic Drugs: Glutamate Antagonists
1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
01:08Antiepileptic Drugs: Sodium Channel Blockers
2.1K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
895
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
895
01:17Antiepileptic Drugs: Calcium Channel Blockers
1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K